Esperion Therapeutics, Inc. (ESPR)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Esperion Therapeutics, Inc. (ESPR)
Go deeper and ask any question about ESPR
Company Performance
Current Price
as of Sep 13, 2024$1.91
P/E Ratio
N/A
Market Cap
$374.79M
Description
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Metrics
Overview
- HQAnn Arbor, MI
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerESPR
- Price$1.91+9.14%
Trading Information
- Market Cap$374.79M
- Float98.94%
- Average Daily Volume (1m)3,189,962
- Average Daily Volume (3m)5,977,390
- EPS-$0.84
Company
- Revenue$277.79M
- Rev Growth (1yr)186.33%
- Net Income-$61.93M
- Gross Margin78.85%
- EBITDA Margin3.51%
- EBITDA$2.59M
- EV$786.45M
- EV/Revenue2.83
- P/EN/A
- P/S1.30
Documents
SEC Filings
Earnings Calls
Factset Street Account
Factset